173 related articles for article (PubMed ID: 8246287)
1. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival.
Winter SF; Sekido Y; Minna JD; McIntire D; Johnson BE; Gazdar AF; Carbone DP
J Natl Cancer Inst; 1993 Dec; 85(24):2012-8. PubMed ID: 8246287
[TBL] [Abstract][Full Text] [Related]
2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
[TBL] [Abstract][Full Text] [Related]
5. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters.
Vural B; Chen LC; Saip P; Chen YT; Ustuner Z; Gonen M; Simpson AJ; Old LJ; Ozbek U; Gure AO
Cancer; 2005 Jun; 103(12):2575-83. PubMed ID: 15880380
[TBL] [Abstract][Full Text] [Related]
6. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
[TBL] [Abstract][Full Text] [Related]
7. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
8. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
Graus F; Dalmou J; Reñé R; Tora M; Malats N; Verschuuren JJ; Cardenal F; Viñolas N; Garcia del Muro J; Vadell C; Mason WP; Rosell R; Posner JB; Real FX
J Clin Oncol; 1997 Aug; 15(8):2866-72. PubMed ID: 9256130
[TBL] [Abstract][Full Text] [Related]
9. Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen.
Friedman RS; Bangur CS; Zasloff EJ; Fan L; Wang T; Watanabe Y; Kalos M
J Immunol; 2004 Mar; 172(5):3319-27. PubMed ID: 14978140
[TBL] [Abstract][Full Text] [Related]
10. Expression of an antigen in small cell lung carcinoma lines detected by antibodies from patients with paraneoplastic dorsal root ganglionpathy.
Budde-Steffen C; Anderson NE; Rosenblum MK; Posner JB
Cancer Res; 1988 Jan; 48(2):430-4. PubMed ID: 2825975
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
[TBL] [Abstract][Full Text] [Related]
12. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy.
Galanis E; Frytak S; Rowland KM; Sloan JA; Lennon VA
Cancer Immunol Immunother; 1999; 48(2-3):85-90. PubMed ID: 10414461
[TBL] [Abstract][Full Text] [Related]
13. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
[TBL] [Abstract][Full Text] [Related]
14. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
16. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
18. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
19. Extracts of lung cancer cells reveal antitumour antibodies in sera of patients with lung cancer.
Bazhin AV; Savchenko MS; Shifrina ON; Chikina SY; Goncharskaia ; Jaques G; Chuchalin AG; Philippov PP
Eur Respir J; 2003 Feb; 21(2):342-6. PubMed ID: 12608451
[TBL] [Abstract][Full Text] [Related]
20. Serum antibodies to retinal antigens in lung cancer and sarcoidosis.
Jankowska R; Witkowska D; Porebska I; Kuropatwa M; Kurowska E; Gorczyca WA
Pathobiology; 2004; 71(6):323-8. PubMed ID: 15627843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
